TLR7 is thought to contribute to the development of SLE, so a clinical trial was performed to study the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of DS-7011a when administered via intravenous and subcutaneous doses [48]. The gene discussed is TLR7; the disease is systemic lupus erythematosus.